Clontech/Lentiviral Tet-On 3G inducible expression systems/Each/631187

价格
¥590000.00
货号:631187
浏览量:127
品牌:Clontech
服务
全国联保
正品保证
正规发票
签订合同
商品描述

Lentiviral gene transfer technology with the power and versatility of our state-of-the-art tetracycline-regulated gene expression system

This page describes a two-vector lentivirus format for inducible expression. Click the link to learn more about our all-in-oneLenti-X Tet-One inducible expression systems.Lenti-X Tet-On 3G inducible expression systems combine the broad cellular tropism of lentiviral gene transfer technology with the power and versatility of our state-of-the-art tetracycline-regulated gene expression system.

This page describes a two-vector lentivirus format for inducible expression. Click the link to learn more about our all-in-one Lenti-X Tet-One inducible expression systems. Lenti-X Tet-On 3G inducible expression systems combine the broad cellular tropism of lentiviral gene transfer technology with the power and versatility of our state-of-the-art tetracycline-regulated gene expression system. The lentiviral Tet-On-3G system consists of two lentiviral vectors: a regulator vector that stably expresses the Tet-On 3G transactivator protein, and a response vector that contains the TRE3G promoter that controls the expression of your transgene. Also included are a control response vector for luciferase expression, and our premium Lenti-X Packaging Single Shots (VSV-G).

How it works

Doxycycline-controlled transactivators are fusion proteins that contain a TetR-derived DNA binding domain joined to three minimal transcription activation domains from VP16 (Tet-On 3G). With very high specificity, the transactivator recognizes and binds to a tetracycline response element (TRE) that is located in the PTRE3G promoter of pLVX-TRE3G, into which you clone your gene of interest. Binding of the transactivator to the TRE promoter results in strong activation of the downstream gene. The Tet-On 3G system is the premium, third-generation version of the technology, with the tightest TRE promoter and most sensitive transactivator. TheTet-Onesystem uses the same components but assembled on a single vector.

In all Tet-On systems, gene expression is activated by the addition of Dox to the growth medium, while in Tet-Off systems, transcription is activated by its withdrawal.

High-titer lentiviral packaging

Our Lenti-X Packaging Single Shots (VSV-G), supplied with each system, generate superior titers compared to most commercially available packaging systems.

 More Less
美国Clontech www.clontech.com www.takara.com.cn www.takara-bio.com www.takara.co.jp 2005年7月1日,日本最大的生物工程公司TaKaRa公司据说花费了6千万美元成功此收购计划已经于2005年8月底完成,Clontech已成为TaKaRa全资子公司。美国Clontech是1984年由华人方瑞贤创立的,一度曾经是众多海外华人的骄傲。因为方瑞贤创立的是全美第一家,也是建立了最大的分子生物公司,更重要的是Clontech建立了生物技术中建立基因文库的模式。在Clontech被BD收购时已有四百名员工,包括六十五位博士,拥有五十多个专利,产品已达两千多个,堪称全球数一,数二的基因库,提供全球三十多个国家基因实验室或学术界做研究之用。该公司有曾于预期四,预期五,预期八及预期九年被圣荷西及旧金山商业报纸选为一百个成长速度的私人公司。Clontech公司一直锐意进取,其开发的产品多次获得全美R&D100金奖。产品范围包括基因识别,基因表达,基因功能研究,大家熟悉的Smart Race,Altas DNA矩阵,SSH消减杂交,MTN膜,多色荧光蛋白载体,MatchMaker酵母双杂交系列也在其中。TaKaRa公司于1979年年从生产限制性内切酶起步,首先将PCR技术引入日本市场,并逐渐成为日本生命科学研究领域领先的公司.TaKaRa在2004年财政年度试剂销售达到118亿日元(1十亿美元左右),其中85%的收益来自于日本本土市场,其他有部分来自于中国等亚洲市场。此次收购会给Takara带来以下收益:极大地丰富Takara原来的产品线;迅速扩大TaKaRa在欧美市场的份额,因为Clontech 70%以上的销售是来自于欧美,而Takara 85%的收益来自于日本本土市场。本次收购将全面扩展日本产品在欧美的销售。另外宝将整合并加强日本本土和位于美国的Clontech公司研发部,加快产品的开发,提高宝在全球生命科学研究市场的份额。